WJTOG3405

一行要約

EGFR 変異陽性の未治療 NSCLC における Gefitinib vs Cisplatin/Docetaxel の日本 phase III。PFS HR 0.489 (9.2 vs 6.3 mo) で有意な PFS 延長を示し、NEJ002 と同時期に発表されて EGFR 変異選択による 1L TKI 治療を二重に確認した companion trial。

試験デザイン

• 対象: EGFR 変異陽性 (ex19del or L858R)、Stage IIIB/IV or 術後再発 NSCLC、未治療、PS 0-1、N=172 (1:1)、日本国内 36 施設
• 介入群 (n=86) : Gefitinib 250 mg/day
• 対照群 (n=86) : Cisplatin 80 mg/m2 + Docetaxel 60 mg/m2 Q3W、3-6 cycles
• 層別化: 性別、PS (0 vs 1)、Stage (IIIB vs IV vs 再発)、変異タイプ (ex19del vs L858R)
• 主要評価項目: PFS
• 登録 ID: UMIN000000539 (NEJ002 とは別登録)

主要結果

• PFS (primary) : HR 0.489 (95% CI 0.336–0.710, p<0.0001)、median 9.2 vs 6.3 mo
• ORR: 62.1% vs 32.2%
• OS: Median 34.8 vs 37.3 mo (HR 1.185, p=0.211) — OS は化療群で numerically 長い (crossover + 後治療の影響)
• Mutation 別: ex19del PFS HR 0.39、L858R PFS HR 0.61 — NEJ002 と同様に ex19del で顕著な benefit
• Grade ≥3 AE: Gefitinib で肝機能障害 (ALT 上昇)、皮疹。化療群で好中球減少、悪心嘔吐
• ILD: Gefitinib 群で 2 例 (2.3%) — NEJ002 よりやや低頻度

臨床的意義

• NEJ002 との相互検証: 独立した試験が同時期に EGFR+ 1L TKI の PFS benefit を確認。2 試験の結果が一致したことで evidence の信頼性が確保され、EGFR 変異検査の global 普及を加速
• 日本からの precision medicine 発信: 2010 年の NEJM / Lancet Oncology 同時掲載は日本の lung cancer 臨床研究の国際的プレゼンスを確立
• OS paradox: Gefitinib 群が PFS で圧勝しながら OS では numerically 劣る結果は、crossover の影響と同時に「PFS と OS の乖離」が EGFR-TKI 試験の共通課題であることを早期に示した
• 化療レジメンの違い: NEJ002 は Carboplatin/Paclitaxel、WJTOG3405 は Cisplatin/Docetaxel — 異なるプラチナ doublet に対する TKI 優位性を証明

Open Questions

• WJTOG3405 cohort のリアルワールド長期予後: 10+ 年の sequential therapy を含む全生存の実態
• Cisplatin/Docetaxel vs Carboplatin/Pemetrexed の後治療への影響: 1L 化療レジメンの違いが後治療 response に与える影響
• EGFR 変異検査法の evolution: 2010 年当時の direct sequencing → 現在の NGS / liquid biopsy への transition

重要論文 Top 10

1. Mitsudomi et al. LancetOncol 2010 — Primary publication — PFS HR 0.489、EGFR+ 1L 確認
2. Yoshioka et al. (OS update) — OS final — crossover の影響で OS 差なし
3. ★★★★★ Maemondo et al. NEnglJMed 2010 (NEJ002) — Companion trial — 同時期発表
4. Mok et al. (IPASS) — IPASS — EGFR selection の先駆
5. ★★★★★ Rosell et al. LancetOncol 2012 (EURTAC) — Western EGFR+ 1L — non-Asian confirmation

関連エンティティ・概念

• 薬剤: Gefitinib / Cisplatin / Docetaxel
• 関連試験: NEJ002 (companion trial) / IPASS (selection 先駆) / EURTAC (Western 確認) / FLAURA (3rd-gen 1L) / LUX-Lung-3 (2nd-gen 1L)
• 関連遺伝子: EGFR (ex19del, L858R)
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 34 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Oncogene and genetics

• Li et al. JClinOncol 2013 — Genotyping and genomic profiling of non-small-cell lung cancer implications for current and future therapies
• Du et al. MolCancer 2018 — Mechanisms of receptor tyrosine kinase activation in cancer

Clinical-Methodology

• Travis et al. JThoracOncol 2011 — International association for the study of lung canceramerican thoracic societyeuropean respiratory society

Clinical-NSCLC-Driver-Other

• Johnson et al. JClinOncol 2014 — Recent clinical advances in lung cancer management

Clinical-NSCLC-EGFR

• Inoue et al. AnnOncol 2013 — Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for
• Lee et al. AnnOncol 2013 — Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with
• Sugawara et al. AnnOncol 2015 — Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously
• Paz-Ares et al. AnnOncol 2017 — Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer overall survival
• Rolfo et al. CancerTreatRev 2014 — Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
• Bronte et al. CritRevOncolHematol 2014 — Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment
• Sequist et al. JClinOncol 2008 — First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
• Han et al. JClinOncol 2012 — First-SIGNAL first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma
• Lee et al. JClinOncol 2015 — Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after
• Cho et al. JClinOncol 2020 — Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations A multicenter, open-label,
• Haratake et al. JTOClinResRep 2020 — Optimizing sequential treatment with EGFR tyrosine kinase inhibitor with a simulation of the T790M mutation rate in
• Mitsudomi et al. LancetOncol 2010 — Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the
• Zhou et al. LancetOncol 2011 — Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell
• Rosell et al. LancetOncol 2012 — Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR
• Zhang et al. LancetOncol 2012 — Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung
• Wu et al. LancetOncol 2014 — Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung
• OKane et al. LungCancer 2017 — Uncommon EGFR mutations in advanced non-small cell lung cancer
• Kobayashi et al. MolCancerTher 2017 — Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung
• Mok et al. NEnglJMed 2009 — Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
• Maemondo et al. NEnglJMed 2010 — Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
• Sequist et al. NEnglJMed 2015 — Rociletinib in EGFR-mutated non-small-cell lung cancer
• Mok et al. NEnglJMed 2017 — Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer
• Soria et al. NEnglJMed 2018 — Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
• Ramalingam et al. NEnglJMed 2020 — Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC
• Asao et al. RespirInvestig 2019 — Resistance to molecularly targeted therapy in non-small-cell lung cancer
• Carnio et al. SeminOncol 2014 — Extending survival of stage IV non-small cell lung cancer